Cy­ti­va pledges $52.5M in­to South Ko­re­an op­er­a­tions as it ex­pands glob­al plans

3 weeks ago
Manufacturing

Glax­o­SmithK­line, Mer­ck KGaA of­fi­cial­ly call it quits on $4B part­ner­ship for flail­ing can­cer drug

3 weeks ago
R&D

Con­tin­u­ing to chart post-Covid path, Mod­er­na will build new sci­ence cen­ter near Mass­a­chu­setts head­quar­ters

3 weeks ago
Pharma

Mer­ck, wad­ing even fur­ther in­to rare dis­ease, inks $11.5B deal for Ac­celeron and its po­ten­tial PAH block­buster

3 weeks ago
Deals

SEC charges ex-Gold­man Sachs an­a­lyst with il­le­gal­ly prof­it­ing off bio­phar­ma merg­ers in in­sid­er trad­ing scheme

3 weeks ago
People

FDA+ guid­ance roundup: Ben­e­fit-risk as­sess­ments, RWE to sup­port reg­u­la­to­ry de­ci­sion-mak­ing, and more

4 weeks ago
FDA+

Ma­jor Mass­a­chu­setts hos­pi­tals de­cide against us­ing Bio­gen's Aduhelm, with the help of a for­mer FDA ad­comm mem­ber

4 weeks ago
Pharma

In bid to at­tract more R&D in­no­va­tion, Eu­rope looks to rewrite its phar­ma leg­is­la­tion

4 weeks ago
Pharma

Ed­i­tas' CRISPR-based eye ther­a­py proves safe, but the ju­ry's still out on whether it works

4 weeks ago
R&D
Cell/Gene Tx

FDA calls for re­peat bioe­quiv­a­lence stud­ies af­ter un­cov­er­ing 'in­valid' da­ta from two In­di­an CROs

4 weeks ago
Outsourcing
FDA+

As­traZeneca wa­gers on $500M buy­out, plucks PhI­II drug for Alex­ion’s rare dis­ease pipeline — and jumps straight in­to risky field

4 weeks ago
Deals

Safe­ty fears force Pfiz­er to change piv­otal DMD gene ther­a­py tri­al pro­to­col

4 weeks ago
R&D
Cell/Gene Tx

George Church, his stu­dents, and top VCs go na­tion­wide with a biotech train­ing camp

4 weeks ago
Startups

Bio­gen can't es­cape co­pay kick­back law­suits as Hu­mana al­leges 'seed­ing and sweep­ing' scheme

4 weeks ago
Pharma

Bio­haven turns out a dud in fa­tal neu­rode­gen­er­a­tive dis­ease, cast­ing doubt on drug's chances in ALS

4 weeks ago
R&D

Mer­ck, Pfiz­er end patent feud over pneu­mo­coc­cal vac­cines with roy­al­ty-cen­tered set­tle­ment

4 weeks ago
Pharma

DE­VEL­OP­ING News: Ac­celeron ne­go­ti­at­ing $11B buy­out; 11 promis­ing biotech star­tups; Changes ga­lore at No­var­tis; #ES­MO21 high­lights; and more

4 weeks ago
Weekly

Days of heat­ed ru­mors cul­mi­nate in a re­port that Ac­celeron is in ad­vanced buy­out talks

4 weeks ago
Deals
R&D

New ARIA cas­es dog Bio­gen's Aduhelm launch in an­oth­er po­ten­tial blow to block­buster hopes — an­a­lyst

4 weeks ago
FDA+

Mi­cro­cap gene ther­a­py play­er says three chil­dren suf­fered se­ri­ous side ef­fects in PhI/II study

4 weeks ago
R&D
Cell/Gene Tx

Lon­za un­veils new ex­pan­sion plans at Swiss man­u­fac­tur­ing sites, cap­ping off a very busy pan­dem­ic

4 weeks ago
Manufacturing

Catal­ent inks deal with Phath­om to make GI drug at re­cent­ly-ren­o­vat­ed Ken­tucky site

4 weeks ago
Outsourcing
Manufacturing

UNC re­searchers re­port a new way to charge CAR-T against sol­id tu­mors

4 weeks ago
Discovery
Cell/Gene Tx

Fol­low­ing con­tro­ver­sial Aduhelm ap­proval, DC-based neu­rol­o­gy cen­ter bans Bio­gen rep­re­sen­ta­tives from its of­fices — re­port

4 weeks ago
Pharma
FDA+
First page Previous page 1234567 Next page Last page